Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germline mutation and non-CHEK2 somatic mutation gene signatures

Cell Cycle

Volumn 13, Issue 14, 2014, Pages 2262-2280

  Ow, Ghim Siong ^a   Ivshina, Anna V ^a   Fuentes, Gloria ^a,b   Kuznetsov, Vladimir A ^a,c,d  

^a BIOINFORMATICS INSTITUTE   (Singapore)

^b RIKEN   (Japan)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biomarker; Cancer driver mutation; Cancer sub type; CHEK2; Chemotherapy resistance; Diagnostics; Gene signature; High grade serous ovarian carcinoma; MLL4; Mutations; Patient's stratification; Prognosis; RPS6KA2; Survival analysis

Indexed keywords

ADAMTSL3 PROTEIN; BRCA1 PROTEIN; CHECKPOINT KINASE 2; ENAH PROTEIN; GL12 PROTEIN; GYPB PROTEIN; KARYOPHERIN ALPHA; LRRN2 PROTEIN; MAP3K6 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 15; MLL4 PROTEIN; PROTEIN; PROTEIN KINASE; PROTEIN P53; PTK2B PROTEIN; RPS6KA2 PROTEIN; RSU1 PROTEIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; CHEK2 PROTEIN, HUMAN; TUMOR MARKER;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DAMAGE; DNA REPAIR; EARLY DIAGNOSIS; ENZYME PHOSPHORYLATION; FEMALE; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; GERMLINE MUTATION; HIGH GRADE SEROUS OVARIAN CARCINOMA; HUMAN; HUMAN TISSUE; MISMATCH REPAIR; MOLECULAR DYNAMICS; MUTATION RATE; NUCLEAR LOCALIZATION SIGNAL; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; BIOLOGY; CANCER GRADING; CLUSTER ANALYSIS; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; KAPLAN MEIER METHOD; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; TIME; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; CHECKPOINT KINASE 2; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GERM-LINE MUTATION; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM GRADING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904510145     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.29271     Document Type: Article

References (70)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138
2. Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol 2009; 4:287-313; PMID:18842102; http://dx.doi.org/10.1146/annurev.pathol.4.110807.092246
3. Tuma RS. Origin of ovarian cancer may have implications for screening. J Natl Cancer Inst 2010; 102:11-3; PMID:20023201; http://dx.doi.org/10.1093/jnci/ djp495
4. Mankoo PK, Shen R, Schultz N, Levine DA, Sander C. Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. PLoS One 2011; 6:e24709; PMID:22073136; http://dx.doi.org/10.1371/journal.pone. 0024709
5. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15; PMID:21720365; http://dx.doi.org/10. 1038/nature10166
6. Tang Z, Ow GS, Thiery JP, Ivshina AV, Kuznetsov VA. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. Int J Cancer 2014; 134:306-18; PMID:23825028
7. Matias-Guiu X, Davidson B. Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch 2014; 464:315-31; PMID:24504546; http://dx.doi.org/10.1007/s00428-013-1509-y
8. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505:495-501; PMID:24390350; http://dx.doi.org/10.1038/nature12912
9. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011; 108:18032-7; PMID:22006311; http://dx.doi.org/10.1073/pnas.1115052108
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
11. McGowan CH. Checking in on Cds1 (Chk2): A checkpoint kinase and tumor suppressor. Bioessays 2002; 24:502-11; PMID:12111733; http://dx.doi.org/10.1002/ bies.10101
12. Baysal BE, DeLoia JA, Willett-Brozick JE, Goodman MT, Brady MF, Modugno F, Lynch HT, Conley YP, Watson P, Gallion HH. Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol 2004; 95:62-9; PMID:15385111; http://dx.doi.org/10.1016/j.ygyno.2004.07.015
13. Szymanska-Pasternak J, Szymanska A, Medrek K, Imyanitov EN, Cybulski C, Gorski B, Magnowski P, Dziuba I, Gugala K, Debniak B, et al. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol 2006; 102:429-31; PMID:16828850; http://dx.doi.org/10.1016/j.ygyno.2006. 05.040
14. Krylova NY, Ponomariova DN, Sherina NY, Ogorodnikova NY, Logvinov DA, Porhanova NV, Lobeiko OS, Urmancheyeva AF, Maximov SY, Togo AV, et al. CHEK2 1100 delC mutation in Russian ovarian cancer patients. Hered Cancer Clin Pract 2007; 5:153-6; PMID:19725991; http://dx.doi.org/10.1186/1897-4287-5-3-153
15. Słojewski M, Złowocka E, Cybulski C, Górski B, Debniak T, Wokołorczyk D, Matyjasik J, Sikorski A, Lubiński J. CHEK2 germline mutations correlate with recurrence rate in patients with superficial bladder cancer. Ann Acad Med Stetin 2008; 54:115-21; PMID:19839522
16. Angelova SG, Krasteva ME, Gospodinova ZI, Georgieva EI. CHEK2 gene alterations independently increase the risk of death from breast cancer in Bulgarian patients. Neoplasma 2012; 59:622-30; PMID:22862163; http://dx.doi.org/10.4149/neo-2012-079
17. Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 2007; 25:64-9; PMID:17132695; http://dx.doi.org/10.1200/JCO.2006.06.3024
18. de Bock GH, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet 2004; 41:731-5; PMID:15466005; http://dx.doi.org/10.1136/jmg.2004.019737
19. Simon M, Ludwig M, Fimmers R, Mahlberg R, Müller-Erkwoh A, Köster G, Schramm J. Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme. Neurosurgery 2006; 59:1078-85, discussion 1085; PMID:17016233
20. Barillot E, Calzone L, Hupé P, Vert J, Zinovyev A. Computation Systems Biology of Cancer. London: CRC Press, 2012.
21. Czech A, Fedyunin I, Zhang G, Ignatova Z. Silent mutations in sight: co-variations in tRNA abundance as a key to unravel consequences of silent mutations. Mol Biosyst 2010; 6:1767-72; PMID:20617253; http://dx.doi.org/10. 1039/c004796c
22. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003; 12:205-16; PMID:12554675; http://dx.doi.org/10.1093/hmg/ddg055
23. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-8; PMID:17185560; http://dx.doi.org/10.1126/science.1135308
24. Kuznetsov VA. Family of skewed distributions associated with the gene expression and proteome evolution. Signal Process 2003; 83:889-910; http://dx.doi.org/10.1016/S0165-1684(02)00481-4
25. Kuznetsov VA. Hypergeometric Model of Evolution of Conserved Protein Coding Sequences in the Proteomes. Fluctuation and Noise Letters 2003; 3:L295-324; http://dx.doi.org/10.1142/S0219477503001397
26. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 2013; 3:246-59; PMID:23318258; http://dx.doi.org/10.1016/j.celrep.2012.12. 008
27. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009; 76:1-18; PMID:19659756; http://dx.doi.org/10.1111/j.1399-0004.2009.01230.x
28. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013; 231:21-34; PMID:23780408; http://dx.doi.org/10.1002/ path.4230
29. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, et al.; EMBRACE; kConFab Investigators; Cancer Genome Atlas Research Network. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012; 307:382-90; PMID:22274685; http://dx.doi.org/10.1001/jama. 2012.20
30. McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P, Narod SA. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 2013; 105:141-8; PMID:23257159; http://dx.doi.org/10.1093/jnci/djs494
31. Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, et al. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 2008; 3:e3062; PMID:18725978; http://dx.doi.org/10.1371/journal.pone. 0003062
32. Motakis E, Ivshina AV, Kuznetsov VA. Data-driven approach to predict survival of cancer patients: estimation of microarray genes' prediction significance by Cox proportional hazard regression model. IEEE Eng Med Biol Mag 2009; 28:58-66; PMID:19622426; http://dx.doi.org/10.1109/MEMB.2009.932937
33. Magrane M, Consortium U. UniProt Knowledgebase: a hub of integrated protein data. Database (Oxford) 2011; 2011:bar009; PMID:21447597; http://dx.doi.org/10.1093/database/bar009
34. Dinkel H, Chica C, Via A, Gould CM, Jensen LJ, Gibson TJ, Diella F. Phospho.ELM: a database of phosphorylation sites - update 2011. Nucleic Acids Res 2011; 39:D261-7; PMID:21062810; http://dx.doi.org/10.1093/nar/gkq1104
35. Yoda A, Xu XZ, Onishi N, Toyoshima K, Fujimoto H, Kato N, Oishi I, Kondo T, Minami Y. Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1. J Biol Chem 2006; 281:24847-62; PMID:16798742; http://dx.doi.org/10.1074/ jbc.M600403200
36. Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 1999; 294:1351-62; PMID:10600390; http://dx.doi.org/10.1006/jmbi.1999.3310
37. Gnad F, Ren S, Cox J, Olsen JV, Macek B, Oroshi M, Mann M. PHOSIDA (phosphorylation site database): management, structural and evolutionary investigation, and prediction of phosphosites. Genome Biol 2007; 8:R250; PMID:18039369; http://dx.doi.org/10.1186/gb-2007-8-11-r250
38. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM; Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45:1113-20; PMID:24071849; http://dx.doi.org/10.1038/ng.2764
39. Cai Z, Chehab NH, Pavletich NP. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. Mol Cell 2009; 35:818-29; PMID:19782031; http://dx.doi.org/10.1016/j.molcel.2009.09.007
40. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234:779-815; PMID:8254673; http://dx.doi.org/10.1006/jmbi.1993.1626
41. Zannini L, Lecis D, Lisanti S, Benetti R, Buscemi G, Schneider C, Delia D. Karyopherin-alpha2 protein interacts with Chk2 and contributes to its nuclear import. J Biol Chem 2003; 278:42346-51; PMID:12909615; http://dx.doi.org/10. 1074/jbc.M303304200
42. Nakai K, Horton P. PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci 1999; 24:34-6; PMID:10087920; http://dx.doi.org/10.1016/S0968-0004(98)01336-X
43. Kosugi S, Hasebe M, Tomita M, Yanagawa H. Systematic identification of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of composite motifs. Proc Natl Acad Sci U S A 2009; 106:10171-6; PMID:19520826; http://dx.doi.org/10.1073/pnas.0900604106
44. Zhang P, Gao W, Li H, Reed E, Chen F. Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells. Biochem Biophys Res Commun 2005; 328:567-72; PMID:15694385; http://dx.doi.org/10.1016/ j.bbrc.2005.01.007
45. He Z, Yang C, Guo G, Li N, Yu W. Motif-All: discovering all phosphorylation motifs. BMC Bioinformatics 2011; 12(Suppl 1):S22; PMID:21342552; http://dx.doi.org/10.1186/1471-2105-12-S1-S22
46. Amanchy R, Kandasamy K, Mathivanan S, Periaswamy B, Reddy R, Yoon WH, Joore J, Beer MA, Cope L, Pandey A. Identification of Novel Phosphorylation Motifs Through an Integrative Computational and Experimental Analysis of the Human Phosphoproteome. J Proteomics Bioinform 2011; 4:22-35; PMID:21720494; http://dx.doi.org/10.4172/jpb.1000163
47. Lahiry P, Torkamani A, Schork NJ, Hegele RA. Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet 2010; 11:60-74; PMID:20019687; http://dx.doi.org/10.1038/nrg2707
48. Tsatsanis C, Spandidos DA. The role of oncogenic kinases in human cancer (Review). [Review]. Int J Mol Med 2000; 5:583-90; PMID:10812005
49. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003; 2:296-313; PMID:12669029; http://dx.doi.org/10.1038/nrd1066
50. Pearson MA, Fabbro D. Targeting protein kinases in cancer therapy: a success? Expert Rev Anticancer Ther 2004; 4:1113-24; PMID:15606337; http://dx.doi.org/10.1586/14737140.4.6.1113
51. Hofree M, Shen JP, Carter H, Gross A, Ideker T. Network-based stratification of tumor mutations. Nat Methods 2013; 10:1108-15; PMID:24037242; http://dx.doi.org/10.1038/nmeth.2651
52. Williams LH, Choong D, Johnson SA, Campbell IG. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin Cancer Res 2006; 12:6967-72; PMID:17145815; http://dx.doi.org/10.1158/1078-0432.CCR-06- 1770
53. Jobson AG, Lountos GT, Lorenzi PL, Llamas J, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid 4-[1- (guanidinohydrazone)-ethyl]-phenylamide]. J Pharmacol Exp Ther 2009; 331:816-26; PMID:19741151; http://dx.doi.org/10.1124/jpet.109.154997
54. Yu Q, Rose JH, Zhang H, Pommier Y. Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett 2001; 505:7-12; PMID:11557032; http://dx.doi.org/10.1016/S0014-5793(01)02756-9
55. Vakifahmetoglu H, Olsson M, Tamm C, Heidari N, Orrenius S, Zhivotovsky B. DNA damage induces two distinct modes of cell death in ovarian carcinomas. Cell Death Differ 2008; 15:555-66; PMID:18064041; http://dx.doi.org/10.1038/sj.cdd. 4402286
56. Ghosh JC, Dohi T, Raskett CM, Kowalik TF, Altieri DC. Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res 2006; 66:11576-9; PMID:17178848; http://dx.doi.org/10.1158/0008-5472.CAN-06-3095
57. Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. Gynecol Oncol 2014; PMID:24657486; http://dx.doi.org/10.1016/j.ygyno.2014.03.557
58. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8:118-27; PMID:16632515; http://dx.doi.org/10.1093/biostatistics/kxj037
59. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, et al.; International Cancer Genome Consortium. International network of cancer genome projects. Nature 2010; 464:993-8; PMID:20393554; http://dx.doi.org/10.1038/nature08987
60. Karolchik D, Hinrichs AS, Kent WJ. The UCSC Genome Browser. Curr Protoc Bioinformatics 2012; Chapter 1:Unit1 4.
61. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004; 20:1453-4; PMID:14871861; http://dx.doi.org/10.1093/ bioinformatics/bth078
62. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95:14863-8; PMID:9843981; http://dx.doi.org/10.1073/pnas.95.25.14863
63. Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44-57; PMID:19131956; http://dx.doi.org/10.1038/nprot.2008.211
64. Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg 2010; 143:331-6; PMID:20723767; http://dx.doi.org/10.1016/j.otohns.2010.05.007
65. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, Baker NA. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res 2007; 35:W522-5; PMID:17488841; http://dx.doi.org/10.1093/nar/gkm276
66. Case DA, Darden TA. T.E. Cheatham I, Simmerling CL, Wang J, Duke RE, et al. AMBER 12. University of California, San Francisco., 2012.
67. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 2006; 65:712-25; PMID:16981200; http://dx.doi.org/10.1002/prot.21123
68. Götz AW, Williamson MJ, Xu D, Poole D, Le Grand S, Walker RC. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 1. Generalized Born. J Chem Theory Comput 2012; 8:1542-55; PMID:22582031; http://dx.doi.org/10.1021/ct200909j
69. Pereira M, Verma CS, Fuentes G. Differences in the binding affinities of ErbB family: heterogeneity in the prediction of resistance mutants. PLoS One 2013; 8:e77054; PMID:24194858; http://dx.doi.org/10.1371/journal.pone.0077054
70. Schrodinger, LLC. The PyMOL Molecular Graphics System, Version 1.3r1. 2010